Serum carnitine levels in chronic hepatitis C patients before and after lymphoblastoid interferon-α treatment

BioDrugs

Volumn 12, Issue 1, 1999, Pages 65-69

  Malaguarnera, Mariano ^a   Restuccia, Salvatore ^a   Di Fazio, Ignazio ^a   Zoccolo, Anna Maria ^a   Ferlito, Laura ^a   Bentivegna, Prospera ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAN1 INTERFERON; CARNITINE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; LIPOPROTEIN BLOOD LEVEL; LYMPHOBLASTOID CELL; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032789465     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199912010-00007     Document Type: Article

References (18)

1. 1. Fritz IB. The metabolic consequences of the effects of carnitine on long-chain fatty acid oxidation. In: Gran FC, editor. Cellular compartmentalization and control of fatty acid metabolism. New York: Academic Press, 1968: 39-63
2. 2. Borum PR. Carnitine. Ann Rev Nutr 1983; 3: 233-59
3. 3. Bohmer T. Conversion of butyrobetaine to carnitine in the rat in vivo. Biochim Biophys Acta 1974; 343: 551-7
4. 4. Rebouche CJ. Sites and regulation of carnitine biosynthesis in mammals. Fed Proc 1982; 41: 2848-52
5. 5. Rebouche CJ, Engel AG. Tissue distribution of carnine biosynthetic enzymes in man. Biochim Biophys Acta 1980; 630: 22-9
6. 6. Krahenbuhl S, Reichen J. Carnitine metabolism in patients with chronic liver disease. Hepatology 1997; 25 (1): 148-53
7. 7. Rudman D, Sewell CW, Ansley JD. Deficiency of carnitine in cachectic cirrhotic patients. J Clin Invest 1977; 60: 716-23
8. 8. Becker-Andre M, Hahlbrock K. Absolute mRNA quantification using the ; polymerase chain reaction (PCR): a novel approach by a PCR aided transcript titration assay (PATTY). NUC Aci Res 1989; 17: 9437-46
9. 9. Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: Bergmeyer HU, editor. Methods of enzymatic analysis. New York: Academic Press, 1974; 4: 1831-5
10. 10. Lopez-Virella MF, Stone P, Ellis S, et al. Cholesterol determination in high density lipoproteins separated by their different methods. Clin Chem 1977; 23: 882-4
11. 11. Mcnamara JR, Schefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 1987; 166: 1-8
12. 12. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20
13. 13. Malaguarnera M, Giugno I, Ruello P, et al. Effect of interferon on blood lipids. Clin Drug Invest 1996; 11 (1): 43-8
14. 14. Patton JS, Shepard M, Wilking H, et al. Interferons and tumour necrosis factor have similar catabolic effects on 3T3 L1 cells. Proc Natl Acad Sci U S A 1986; 83: 8313-17
15. 15. Beutler BA, Cerami A. Recombinant interleukin 1 suppress lipoprotein lipase activity in 3T3 L1 cells. J Immunol 1985; 3969-71
16. 16. Saxena U, Witte LD, Goldberg IJ. Tumour necrosis factor induced release of endothelial cell lipoprotein lipase. Atherosclerosis 1990; 10: 470-3
17. 17. Pola P, Savi L, Grilli M, et al. Carnitine in the therapy of dislypidemic patients. Curr Ther Res 1980; 27: 208-16
18. 18. Havel RJ, Kane JP, Kashyap ML. Interchange of apoliproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man. J Clin Invest 1973; 52-32